STOCK TITAN

Moderna president Stephen Hoge gives 400K shares to charity

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Moderna, Inc. President Stephen Hoge exercised options for 76,453 shares on November 16 and 76,452 shares on November 17 at $12.21 per share. He sold 39,160 shares at a weighted-average price of $219.66 on November 16; on November 17 he sold 33,976 shares at a weighted-average $211.45, 5,082 at $212.57 and 157 at $214.19. He gifted 400,000 shares to charity on November 16. The exercises and sales were under a Rule 10b5-1 plan adopted June 15, 2026. As of November 16, reported holdings included 4,116 shares held by Valhalla, LLC and 151,933 shares held directly by a trust for his spouse and children; Hoge disclaims Section 16 beneficial ownership of the trust shares except to the extent of any pecuniary interest.

Insider Hoge Stephen
Role President
Sold 78,375 shs ($16.90M)
Approx. gross sale proceeds $16.90M
Approx. exercise cost $1.87M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F8 76,452 $0.00 $0.00
Exercise Common Stock F1 76,452 $12.21 $933K
Sale Common Stock F1, F4 33,976 $211.45 $7.18M
Sale Common Stock F1, F5 5,082 $212.57 $1.08M
Sale Common Stock F1, F6 157 $214.19 $34K
Exercise Stock Option (Right to Buy) F1, F8 76,453 $0.00 $0.00
Exercise Common Stock F1 76,453 $12.21 $933K
Sale Common Stock F1, F2 39,160 $219.66 $8.60M
Gift Common Stock F3 400,000 $0.00 $0.00
Holding Common Stock -- -- --
Holding Common Stock F7 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 1,311,095 shares (Direct); Common Stock — 4,116 shares (Indirect, By Valhalla, LLC); Common Stock — 151,933 shares (Indirect, By Trust)
Footnotes (8)
  1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $219.54 to $220.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. F3. The reported disposition represents a bona fide charitable gift made by the reporting person.
  4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $211.41 to $212.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  5. F5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $212.50 to $213.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  6. F6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.92 to $214.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  7. F7. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
  8. F8. This option is fully vested and exercisable.
Shares acquired on option exercise 76,453 shares November 16, 2026
Shares acquired on option exercise 76,452 shares November 17, 2026
Option exercise price $12.21 per share Option exercises on November 16 and 17, 2026
November 16 sale 39,160 shares; $219.66 weighted-average price per share November 16, 2026
November 17 sale 33,976 shares; $211.45 weighted-average price per share November 17, 2026
November 17 sale 5,082 shares; $212.57 weighted-average price per share November 17, 2026
November 17 sale 157 shares; $214.19 weighted-average price per share November 17, 2026
Charitable gift 400,000 shares November 16, 2026
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
bona fide charitable gift regulatory
"represents a bona fide charitable gift"
Section 16 beneficial ownership regulatory
"disclaims Section 16 beneficial ownership of these securities"
fully vested and exercisable financial
"This option is fully vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Moderna (MRNA) shares did Stephen Hoge sell, and at what prices?

Stephen Hoge sold 39,160 shares on November 16 at a weighted-average price of $219.66. On November 17, he sold 33,976 shares at a weighted-average $211.45, 5,082 at $212.57 and 157 at $214.19. Each price was a weighted average across multiple transactions; these sales were under a Rule 10b5-1 trading plan adopted June 15, 2026.

How many Moderna (MRNA) shares did Stephen Hoge acquire through option exercises?

He acquired 76,453 common shares on November 16 and 76,452 on November 17, at an exercise price of $12.21 per share. The options were fully vested and exercisable, with a reported expiration date of February 23, 2027.

How many Moderna (MRNA) shares did Stephen Hoge give to charity?

He made a bona fide charitable gift of 400,000 common shares on November 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hoge Stephen

(Last)(First)(Middle)
C/O MODERNA, INC.
325 BINNEY STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M(1)76,453A$12.211,713,018D
Common Stock11/16/2026S(1)39,160D$219.66(2)1,673,858D
Common Stock11/16/2026G400,000D$0(3)1,273,858D
Common Stock11/17/2026M(1)76,452A$12.211,350,310D
Common Stock11/17/2026S(1)33,976D$211.45(4)1,316,334D
Common Stock11/17/2026S(1)5,082D$212.57(5)1,311,252D
Common Stock11/17/2026S(1)157D$214.19(6)1,311,095D
Common Stock4,116IBy Valhalla, LLC
Common Stock151,933IBy Trust(7)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$12.2111/16/2026M(1)76,453 (8)02/23/2027Common Stock76,453$076,452D
Stock Option (Right to Buy)$12.2111/17/2026M(1)76,452 (8)02/23/2027Common Stock76,452$00D
Explanation of Responses:
1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $219.54 to $220.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3. The reported disposition represents a bona fide charitable gift made by the reporting person.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $211.41 to $212.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $212.50 to $213.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.92 to $214.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
7. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
8. This option is fully vested and exercisable.
/s/ James Dillon, as Attorney-in-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading